Kintara Therapeutics Inc expected to post a loss of $3.16 a share - Earnings Preview

TuHURA Biosciences

07/02/2023 19:32

* Kintara Therapeutics Inc  KTRA.OQ   KTRA.O  is expected
to show
no change in quarterly revenue when it reports  results on
February 9 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Kintara
Therapeutics Inc
is for a loss of $3.16 per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "Hold".​

This summary was machine generated February 7 at 19:31 GMT.  All
figures in US dollars  unless otherwise stated